Oppenheimer resumed coverage on Marker Therapeutics with a new price target
$MRKR
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer resumed coverage of Marker Therapeutics with a rating of Buy and set a new price target of $8.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2025 | $8.00 | Buy | Canaccord Genuity |
| 2/17/2022 | $3.00 → $1.00 | Buy → Neutral | Roth Capital |